Staphylococcal biofilm: penetration and bioavailability of vancomycin with or without rifampin

被引：0

作者：

Daffinee, Kathryn E. ^{[1
]}

O'Neill, Emily T. ^{[1
,2
]}

Bleick, Callan R. ^{[2
]}

Williams, Geoff ^{[3
]}

Antoci, Valentin ^{[4
,5
]}

Garcia, Dioscaris ^{[4
,5
]}

LaPlante, Kerry L. ^{[1
,2
,6
]}

机构：

[1] Providence Vet Affairs Med Ctr, Infect Dis Res Program, Providence, RI 02908 USA

[2] Univ Rhode Isl, Coll Pharm, 02881, Ri, Kingston, Jamaica

[3] Brown Univ, Leduc Bioimaging Facil, Div Biol & Med, Providence, RI USA

[4] Brown Univ, Warren Alpert Sch Med, Dept Orthopaed, Providence, RI USA

[5] Rhode Isl Hosp, Diane N Weiss Ctr Orthopaed Trauma Res, Providence, RI USA

[6] Brown Univ, Warren Alpert Med Sch, Div Infect Dis, Providence, RI 02912 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2023年 / 106卷 / 03期

关键词：

Staphylococcus epidermidis; Biofilm; Vancomycin; Rifampin; Microscopy; AUREUS BACTEREMIA; EPIDERMIDIS; DAPTOMYCIN; THERAPY;

D O I：

10.1016/j.diagmicrobio.2023.115947

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We measured antibiotic penetration and bioavailability in staphylococcus biofilms using simulated human-ized concentrations of fluorescent vancomycin plus or minus rifampin. Vancomycin percent recovery across biofilm layers was:upper = 46%, middle = 40%, and lower = 33%. Vancomycin plus rifampin was not signifi-cantly different (P = 0.65). Addition of rifampin did not improve vancomycin penetration across biofilm layers.Published by Elsevier Inc.

引用

页数：3

共 50 条

[31] Biology and Regulation of Staphylococcal Biofilm
Francois, Patrice
Schrenzel, Jacques
Goetz, Friedrich
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (06)
[32] VANCOMYCIN THERAPY OF SEVERE STAPHYLOCOCCAL INFECTIONS
KIRBY, WMM
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1984, 14 : 73 - 78
[33] VANCOMYCIN THERAPY IN SEVERE STAPHYLOCOCCAL INFECTIONS
KIRBY, WMM
REVIEWS OF INFECTIOUS DISEASES, 1981, 3 : S236 - S239
[34] SEVERE STAPHYLOCOCCAL INFECTIONS TREATED WITH VANCOMYCIN
CAFFERKEY, MT
HONE, R
KEANE, CT
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1982, 9 (01) : 69 - 74
[35] THE ANTAGONISTIC EFFECT OF RIFAMPIN UPON CYCLOSPORINE BIOAVAILABILITY
VANBUREN, D
WIDEMAN, CA
RIED, M
GIBBONS, S
VANBUREN, CT
JAROWENKO, M
FLECHNER, SM
FRAZIER, OH
COOLEY, DA
KAHAN, BD
TRANSPLANTATION PROCEEDINGS, 1984, 16 (06) : 1642 - 1645
[36] TREATMENT OF SEVERE STAPHYLOCOCCAL INFECTIONS WITH VANCOMYCIN
WOODLEY, DW
HALL, WH
ANNALS OF INTERNAL MEDICINE, 1961, 55 (02) : 235 - +
[37] Is vancomycin redundant for serious staphylococcal infection?
Gould, Ian M.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 36 : S55 - S57
[38] BIOAVAILABILITY OF RIFAMPIN IN EXPERIMENTAL MURINE TUBERCULOSIS - REPLY
GROSSETT, J
TRUFFOTPERNOT, C
LACROIX, C
JI, B
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (09) : 2066 - 2067
[39] Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model
Jahanbakhsh, Seyedehameneh
Singh, Nivedita B.
Yim, Juwon
Kebriaei, Razieh
Smith, Jordan R.
Lev, Katherine
Tran, T. T.
Rose, Warren E.
Arias, Cesar A.
Rybak, Michael J.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (05)
[40] CHRONIC STAPHYLOCOCCAL OSTEOMYELITIS - TREATMENT WITH REGIMENS CONTAINING RIFAMPIN
NORDEN, CW
FIERER, J
BRYANT, RE
REVIEWS OF INFECTIOUS DISEASES, 1983, 5 : S495 - S501

← 1 2 3 4 5 →